Sai Parenterals sees ₹750 cr revenue this year, will carry peak debt of ₹319 cr
Management guided for ₹750 crore in revenue and a 17% EBITDA margin in FY27, a year it calls the peak for debt as it spends ₹440 cr on capex.
— 1 earlier story on Sai Parenteral's Ltd. →What's new
- Sai Parenterals guided for ₹750 cr revenue and a 17% EBITDA margin in FY27.
- Company is executing a ₹440 cr capex plan, with its Australian facility due by March 2027.
- FY27 is the peak debt year at ₹319 cr net debt; decline is expected from FY28.
Why this matters
The call lays out a clear financial bridge: a big spending year to build assets, followed by a pivot to monetisation. The ₹319 crore debt peak is the cost, and the 2.4 percentage point margin lift from the Nu-Med integration is the promised payoff. Whether the assets deliver as planned is now the core question.
What we're watching
- Execution on the ₹440 cr capex and the March 2027 Adelaide commissioning date.
- Whether Nu-Med backward integration delivers the guided 2.4 pp margin lift starting in Q4.
- The actual trajectory of debt reduction from FY28.
The full read
Sai Parenterals is guiding for ₹750 crore in revenue this year. The margin target is 17%. Those numbers sit on top of a ₹440 crore capex push that will peak the company's balance sheet. Management said FY27 will be the high-water mark for debt, with net debt hitting ₹319 crore before dropping from FY28. The bet is specific: a new facility in Adelaide, due by March 2027, and backward integration at the Nu-Med subsidiary starting in Q4. That integration alone should add 2.4 percentage points to EBITDA margin. The call frames this as the end of the investment cycle and the start of asset monetisation. Not yet.
Questions answered
- What is the revenue and margin target for FY27?
- Management guided for ₹750 crore in revenue and a 17% EBITDA margin for the current fiscal year.
- Why is FY27 the peak debt year?
- The company is funding a ₹440 crore capex programme, which will push net debt to ₹319 crore. Management expects this to be the highest point, with debt declining from FY28.
- How does the Australian acquisition affect margins?
- The Nu-Med acquisition will begin backward integration in the fourth quarter, which management projects will drive a 2.4 percentage point improvement in EBITDA margin.
- What is the timeline for the key Australian asset?
- The Adelaide facility in Australia is scheduled to be commissioned by March 2027.
- Is the ₹750 crore target a large step up?
- The filing does not provide FY26 or FY25 revenue figures, so the scale of the growth target cannot be assessed from this call alone.
Sai Parenteral's Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SAIPARENT →- 27 May 2026 · 4:52 PM IST Sai Parenterals sees ₹750 cr revenue this year, will carry peak debt of ₹319 cr
- 5d ago Sai Parenterals locks in ₹1,300-cr Australian OTC deal, 3.4x annual revenue